Received: 23 March 2019
Accepted: 6 September 2019
First Online: 10 October 2019
Ethics approval and consent to participate
: The study protocol was approved by the Institutional Review Boards at both centers and complied with the Declaration of Helsinki.
: Not applicable.
: TZ: inventor, patent pending CA2994617, AU2018200974, US, February 9, 2018, all rights owned by Aalborg University Hospital, North Denmark Region, speaker for AstraZeneca. BT, SR, AMT, NEB, KJGE, JK and TFH: none. NR: speaker for GE Healthcare. PS: speaker for GE Healthcare, advisory board member (Novartis Pharmaceuticals Corp., Astra Zeneca Pharmaceuticals, Biotronik), research grants Wics, Bayer, GE Healthcare.